<DOC>
	<DOCNO>NCT00083148</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan capecitabine , work different way stop tumor cell divide stop grow die . Irinotecan may help capecitabine kill tumor cell make tumor cell sensitive drug . PURPOSE : This phase I trial study side effect best dose irinotecan capecitabine treat woman advance breast cancer .</brief_summary>
	<brief_title>Irinotecan Capecitabine Treating Women With Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose capecitabine irinotecan woman advance breast cancer . - Determine degree accumulation cell S-phase tumor biopsy patient treat regimen . - Determine dose-limiting toxicity major unusual toxic effect regimen patient . - Determine antitumor activity regimen patient . - Determine pharmacokinetics regimen , include active metabolite SN-38 , patient . - Correlate pharmacokinetic parameter regimen biological change observe patient . - Determine , preliminarily , relationship tumor response modulation S-phase patient treat regimen . OUTLINE : This dose-escalation study . Patients receive irinotecan IV 1.5 hour day 1 , 8 , 22 , 29 oral capecitabine twice daily day 1-14 23-36 . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos irinotecan capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 8-37 patient accrue study within 18-24 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis breast cancer eligible potentially curative therapy study higher priority Advanced disease Tumor accessible biopsy AND irradiate Failed least 1 prior chemotherapy regimen ( include adjuvant chemotherapy ) Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Not specify Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL Hepatic AST ≤ 2 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Renal Creatinine ≤ 1.5 time ULN OR Creatinine clearance ≥ 50 mL/min Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No active uncontrolled bacterial , viral , fungal infection No poor medical risk nonmalignant systemic disease PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Prior irinotecan allow Prior carboplatin allow More 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy Not specify Radiotherapy See Disease Characteristics More 4 week since prior radiotherapy except small port radiotherapy local control Surgery More 4 week since prior major surgery Other No concurrent highdose IV cyclosporine</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>